{"transactions":[{"id":3596,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":1286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":15867,"derivative":{"exercise_price":24.2,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":1286},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3595,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":7999,"derivative":{"exercise_price":24.2,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3594,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":9012,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":620},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3593,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":12824,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":694},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3592,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":1286,"price":24.2,"value":31121.2,"ownership":{"direct":true},"balance_after":82962,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3591,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":24.2,"value":48400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":81676,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3590,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":620,"price":18.7,"value":11594.0,"ownership":{"direct":true},"balance_after":79676,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3589,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":694,"price":12.7,"value":8813.8,"ownership":{"direct":true},"balance_after":79056,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3588,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":928,"price":47.5,"value":44080.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":78362,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3584,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:01:28.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":874,"price":47.5,"value":41515.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":61622,"source":{"system":"sec-edgar","filing":"0000905148-26-004079","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820066/000090514826004079/form4.xml","form_type":"4"}},{"id":3527,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-09-03T22:59:51.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2424,"price":47.5,"value":115140.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan."}],"balance_after":273362,"source":{"system":"sec-edgar","filing":"0000905148-26-004078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190279/000090514826004078/form4.xml","form_type":"4"}},{"id":3524,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-09-03T22:59:19.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":877,"price":47.5,"value":41657.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":50559,"source":{"system":"sec-edgar","filing":"0000905148-26-004077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577899/000090514826004077/form4.xml","form_type":"4"}},{"id":711404,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":31067,"kind":"person","name":"HANNAH ALISON L.","position":1,"cik":"0001645600","reported_name":"HANNAH ALISON L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-11T01:53:28.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended."}],"balance_after":35025,"source":{"system":"sec-edgar","filing":"0000905148-26-003238","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003238/form4.xml","form_type":"4"}},{"id":728060,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:04:28.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":35,"value":87500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes."}],"balance_after":10125,"source":{"system":"sec-edgar","filing":"0000905148-26-003076","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003076/form4.xml","form_type":"4"}},{"id":730917,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:12:01.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003039/form4.xml","form_type":"4"}},{"id":730916,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:59.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":31700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":31700,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":31700},"source":{"system":"sec-edgar","filing":"0000905148-26-003038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003038/form4.xml","form_type":"4"}},{"id":730915,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:59.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003040/form4.xml","form_type":"4"}},{"id":730914,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:59.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":14.9,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-26-003040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003040/form4.xml","form_type":"4"}},{"id":730913,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:57.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003037/form4.xml","form_type":"4"}},{"id":730909,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:57.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003036/form4.xml","form_type":"4"}},{"id":752649,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":13518,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":2181},"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752648,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":1200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":9632,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752647,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":928,"price":29.86,"value":27710.08,"ownership":{"direct":true},"balance_after":78790,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752646,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2181,"price":12.7,"value":27698.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":79718,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752645,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":1200,"price":18.7,"value":22440.0,"ownership":{"direct":true},"balance_after":77537,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752642,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:02:55.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":874,"price":29.86,"value":26097.64,"ownership":{"direct":true},"balance_after":61996,"source":{"system":"sec-edgar","filing":"0000905148-26-002810","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002810/form4.xml","form_type":"4"}},{"id":752641,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:02:24.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":850,"price":29.86,"value":25381.0,"ownership":{"direct":true},"balance_after":34003,"source":{"system":"sec-edgar","filing":"0000905148-26-002809","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002809/form4.xml","form_type":"4"}},{"id":752640,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-06-03T22:01:56.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2424,"price":29.86,"value":72380.64,"ownership":{"direct":true},"balance_after":279593,"source":{"system":"sec-edgar","filing":"0000905148-26-002808","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002808/form4.xml","form_type":"4"}},{"id":752639,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-06-03T22:01:27.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":877,"price":29.86,"value":26187.22,"ownership":{"direct":true},"balance_after":50936,"source":{"system":"sec-edgar","filing":"0000905148-26-002807","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002807/form4.xml","form_type":"4"}},{"id":760610,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:19:05.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":29.17,"value":72925.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."}],"balance_after":12625,"source":{"system":"sec-edgar","filing":"0000905148-26-002724","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002724/form4.xml","form_type":"4"}},{"id":772918,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:50:40.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18250,"source":{"system":"sec-edgar","filing":"0000905148-26-002535","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002535/form4.xml","form_type":"4"}},{"id":772916,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:50:18.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18472,"source":{"system":"sec-edgar","filing":"0000905148-26-002534","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002534/form4.xml","form_type":"4"}},{"id":772915,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":38121,"kind":"person","name":"MILLER MICHAEL PATRICK","position":1,"cik":"0001236514","reported_name":"MILLER MICHAEL PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:49:55.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":5937,"source":{"system":"sec-edgar","filing":"0000905148-26-002533","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002533/form4.xml","form_type":"4"}},{"id":772914,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:49:29.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18250,"source":{"system":"sec-edgar","filing":"0000905148-26-002532","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002532/form4.xml","form_type":"4"}},{"id":772913,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":31067,"kind":"person","name":"HANNAH ALISON L.","position":1,"cik":"0001645600","reported_name":"HANNAH ALISON L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:49:03.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":16375,"source":{"system":"sec-edgar","filing":"0000905148-26-002531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002531/form4.xml","form_type":"4"}},{"id":772911,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46092,"kind":"person","name":"Frohlich Mark W","position":1,"cik":"0001420482","reported_name":"Frohlich Mark W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:48:40.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0000905148-26-002530","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002530/form4.xml","form_type":"4"}},{"id":772912,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:48:13.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":15125,"source":{"system":"sec-edgar","filing":"0000905148-26-002529","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002529/form4.xml","form_type":"4"}},{"id":885683,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-24T21:58:28.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vested monthly over twelve (12) months from the grant date of May 11, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":24,"expiration_date":"2026-05-11","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000905148-26-001015","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826001015/form4.xml","form_type":"4"}},{"id":885682,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T21:58:28.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":4000,"price":36.36,"value":145440.0,"ownership":{"direct":true},"balance_after":12722,"source":{"system":"sec-edgar","filing":"0000905148-26-001015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826001015/form4.xml","form_type":"4"}},{"id":885681,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T21:58:28.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":24,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":16722,"source":{"system":"sec-edgar","filing":"0000905148-26-001015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826001015/form4.xml","form_type":"4"}},{"id":894190,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:09.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":19497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":51813,"source":{"system":"sec-edgar","filing":"0000905148-26-000956","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000956/form4.xml","form_type":"4"}},{"id":894189,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:07.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":53915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":282017,"source":{"system":"sec-edgar","filing":"0000905148-26-000955","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000955/form4.xml","form_type":"4"}},{"id":894188,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:07.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":18894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":34853,"source":{"system":"sec-edgar","filing":"0000905148-26-000953","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000953/form4.xml","form_type":"4"}},{"id":894187,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:06.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":19430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":62870,"source":{"system":"sec-edgar","filing":"0000905148-26-000954","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000954/form4.xml","form_type":"4"}},{"id":894186,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:06.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":20636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":76337,"source":{"system":"sec-edgar","filing":"0000905148-26-000952","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000952/form4.xml","form_type":"4"}},{"id":908104,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:22.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3546,"price":34.62,"value":122762.52,"ownership":{"direct":true},"balance_after":55701,"source":{"system":"sec-edgar","filing":"0000905148-26-000678","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000678/form4.xml","form_type":"4"}},{"id":908105,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:21.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3546,"price":34.62,"value":122762.52,"ownership":{"direct":true},"balance_after":32316,"source":{"system":"sec-edgar","filing":"0000905148-26-000676","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000676/form4.xml","form_type":"4"}},{"id":908102,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:19.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3546,"price":34.62,"value":122762.52,"ownership":{"direct":true},"balance_after":43440,"source":{"system":"sec-edgar","filing":"0000905148-26-000679","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000679/form4.xml","form_type":"4"}},{"id":908100,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:18.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":7607,"price":34.62,"value":263354.34,"ownership":{"direct":true},"balance_after":228102,"source":{"system":"sec-edgar","filing":"0000905148-26-000675","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000675/form4.xml","form_type":"4"}},{"id":908101,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:17.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3758,"price":34.62,"value":130101.96,"ownership":{"direct":true},"balance_after":15959,"source":{"system":"sec-edgar","filing":"0000905148-26-000677","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000677/form4.xml","form_type":"4"}},{"id":919910,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:21:41.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":5718,"price":36.01,"value":205905.18,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":46986,"source":{"system":"sec-edgar","filing":"0000905148-26-000498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000498/form4.xml","form_type":"4"}},{"id":919908,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:21:11.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":5488,"price":36.01,"value":197622.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":59247,"source":{"system":"sec-edgar","filing":"0000905148-26-000497","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000497/form4.xml","form_type":"4"}},{"id":919907,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:50.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":3968,"price":36.01,"value":142887.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":35862,"source":{"system":"sec-edgar","filing":"0000905148-26-000496","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000496/form4.xml","form_type":"4"}},{"id":919906,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":27.4,"exercise_date":"2017-04-19","expiration_date":"2026-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919905,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vested monthly over two (2) years from January 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":27.4,"expiration_date":"2026-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919904,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:33.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":14110,"price":36.01,"value":508101.1,"ownership":{"direct":true},"balance_after":235709,"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919903,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":35424,"price":37,"value":1310688.0,"ownership":{"direct":true},"balance_after":249819,"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919902,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":27.4,"value":1096000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":285243,"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919901,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":35211,"price":37,"value":1302807.0,"ownership":{"direct":true},"balance_after":245243,"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":919900,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:33.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":27.4,"value":1096000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":280454,"source":{"system":"sec-edgar","filing":"0000905148-26-000495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000495/form4.xml","form_type":"4"}},{"id":922583,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":38121,"kind":"person","name":"MILLER MICHAEL PATRICK","position":1,"cik":"0001236514","reported_name":"MILLER MICHAEL PATRICK","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2026-02-03T21:09:48.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal monthly installments over a period beginning on February 1, 2026 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":12000,"derivative":{"exercise_price":34.86,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000905148-26-000482","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000482/form4.xml","form_type":"4"}},{"id":958579,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":10832,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958578,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":2846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":17153,"derivative":{"exercise_price":24.2,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":2846},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958577,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":1987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":14262,"derivative":{"exercise_price":20,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":1987},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958576,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":1667,"price":18.7,"value":31172.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":64235,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958575,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":2846,"price":24.2,"value":68873.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":62568,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958574,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":1987,"price":20,"value":39740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 500 shares of common stock acquired under the Issuer's stock purchase plan."}],"balance_after":59722,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":1038334,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:27:04.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003351","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003351/form4.xml","form_type":"4"}},{"id":1038333,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:54.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003350","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003350/form4.xml","form_type":"4"}},{"id":1038332,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:41.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003349","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003349/form4.xml","form_type":"4"}},{"id":1038331,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:30.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003348","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003348/form4.xml","form_type":"4"}},{"id":1038330,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:19.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":31700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":31700,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":31700},"source":{"system":"sec-edgar","filing":"0000905148-25-003347","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003347/form4.xml","form_type":"4"}},{"id":1132353,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:41.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001936","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001936/form4.xml","form_type":"4"}},{"id":1132352,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:41.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000905148-25-001936","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001936/form4.xml","form_type":"4"}},{"id":1132351,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:31.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001935","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001935/form4.xml","form_type":"4"}},{"id":1132350,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:31.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":9375,"source":{"system":"sec-edgar","filing":"0000905148-25-001935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001935/form4.xml","form_type":"4"}},{"id":1132349,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:19.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001934/form4.xml","form_type":"4"}},{"id":1132348,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46094,"kind":"person","name":"MOOS WALTER H","position":1,"cik":"0001190272","reported_name":"MOOS WALTER H","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:19.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":12722,"source":{"system":"sec-edgar","filing":"0000905148-25-001934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001934/form4.xml","form_type":"4"}},{"id":1132347,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:06.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001933/form4.xml","form_type":"4"}},{"id":1132346,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:06.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000905148-25-001933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001933/form4.xml","form_type":"4"}},{"id":1132345,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":31067,"kind":"person","name":"HANNAH ALISON L.","position":1,"cik":"0001645600","reported_name":"HANNAH ALISON L.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:26:55.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001932","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001932/form4.xml","form_type":"4"}},{"id":1132344,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":31067,"kind":"person","name":"HANNAH ALISON L.","position":1,"cik":"0001645600","reported_name":"HANNAH ALISON L.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:26:55.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":10625,"source":{"system":"sec-edgar","filing":"0000905148-25-001932","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001932/form4.xml","form_type":"4"}},{"id":1132343,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46092,"kind":"person","name":"Frohlich Mark W","position":1,"cik":"0001420482","reported_name":"Frohlich Mark W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:26:40.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":1500,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0000905148-25-001931","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001931/form4.xml","form_type":"4"}},{"id":1132342,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46092,"kind":"person","name":"Frohlich Mark W","position":1,"cik":"0001420482","reported_name":"Frohlich Mark W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:26:40.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0000905148-25-001931","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001931/form4.xml","form_type":"4"}},{"id":1197502,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:36.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":7850,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000905148-25-000980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000980/form4.xml","form_type":"4"}},{"id":1197501,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:36.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":5625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":5625,"derivative":{"exercise_price":35.4,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":5625},"source":{"system":"sec-edgar","filing":"0000905148-25-000980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000980/form4.xml","form_type":"4"}},{"id":1197504,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:27.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":7850,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000905148-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000979/form4.xml","form_type":"4"}},{"id":1197503,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:27.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,875 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,875 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,875 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":6875,"derivative":{"exercise_price":35.4,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0000905148-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000979/form4.xml","form_type":"4"}},{"id":1197500,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:18.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":14.9,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-25-000978","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000978/form4.xml","form_type":"4"}},{"id":1197499,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:04.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":30000,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905148-25-000977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000977/form4.xml","form_type":"4"}},{"id":1197498,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:04.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":26250,"derivative":{"exercise_price":35.4,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0000905148-25-000977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000977/form4.xml","form_type":"4"}},{"id":1197497,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:55:51.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":7850,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000905148-25-000976","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000976/form4.xml","form_type":"4"}},{"id":1197496,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:55:51.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":9,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-25-000976","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000976/form4.xml","form_type":"4"}},{"id":1215707,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46092,"kind":"person","name":"Frohlich Mark W","position":1,"cik":"0001420482","reported_name":"Frohlich Mark W","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-03-10T21:42:13.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal monthly installments over a period beginning on March 6, 2025 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":12000,"derivative":{"exercise_price":19.7,"expiration_date":"2035-03-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000905148-25-000899","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000899/form4.xml","form_type":"4"}},{"id":1280587,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:22.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1734,"price":21.926,"value":38019.684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":57235,"source":{"system":"sec-edgar","filing":"0000905148-25-000413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000413/form4.xml","form_type":"4"}},{"id":1280586,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:22.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":2036,"price":20.921,"value":42595.156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":58969,"source":{"system":"sec-edgar","filing":"0000905148-25-000413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000413/form4.xml","form_type":"4"}},{"id":1280585,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:13.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1796,"price":21.926,"value":39379.096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":51704,"source":{"system":"sec-edgar","filing":"0000905148-25-000412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000412/form4.xml","form_type":"4"}},{"id":1280584,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2451,"kind":"person","name":"Santos David A","position":1,"cik":"0001820066","reported_name":"Santos David A","relationship":{"officer":true,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:13.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":2125,"price":20.921,"value":44457.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":53500,"source":{"system":"sec-edgar","filing":"0000905148-25-000412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000412/form4.xml","form_type":"4"}},{"id":1280583,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:03.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":4400,"price":21.926,"value":96474.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":239454,"source":{"system":"sec-edgar","filing":"0000905148-25-000411","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000411/form4.xml","form_type":"4"}},{"id":1280582,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2427,"kind":"person","name":"RODRIGUEZ RAUL R","position":1,"cik":"0001190279","reported_name":"RODRIGUEZ RAUL R","relationship":{"director":true,"officer":true,"officer_title":"CEO, President"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:03.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":4952,"price":20.921,"value":103600.792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":243854,"source":{"system":"sec-edgar","filing":"0000905148-25-000411","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000411/form4.xml","form_type":"4"}}],"next_cursor":"2025-02-07T01:27:03.000000Z,1280582"}